CSL Bioplasma
CSL Bioplasma Overview
Contact
CSL Bioplasma's
head office
CSL Bioplasma has been Australia’s national fractionator of plasma-derived therapeutics since 1952. Today, Australian Governments continue to choose CSL Bioplasma as Australia’s national plasma fractionator. Regulated by the Therapeutic Goods Administration, a regulator held in high regard worldwide, CSL Bioplasma and the Australian Red Cross Blood Service ensure that the blood and plasma donations made voluntarily by people living in Australia continue to deliver the benefits that self-sufficiency provides. These benefits include a sustainable, reliable and high quality source of plasma-derived therapeutics, developed to treat serious medical conditions including immunodeficiency disorders, a range of haematological and neurological disorders, haemophilia, haemolytic disease of the newborn and trauma. A range of products is also available to provide protection against infectious diseases including hepatitis B, tetanus, chickenpox and cytomegalovirus.
With more than 50 years experience fractionating plasma-derived therapeutics, and strengths in innovation, quality, and safety, CSL Bioplasma has also been chosen as the national plasma fractionator by New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
CSL Bioplasma works with health authorities and blood services in these countries to ensure they experience the benefits that self-sufficiency in plasma-derived therapeutics provides. These benefits include peace-of-mind regarding the quality, safety, cost and assured supply of plasma derived therapeutics fractionated from plasma collected within their own countries.
CSL Bioplasma’s focus on continued excellence in service delivery ensures that our customers are provided with tailored product support, supply chain management and customer service.
Our products
Our product range varies from country to country. Choose a country below to view products available.
Country